M&A Deal Summary

Covidien Acquires Aspect Medical Systems

On November 6, 2009, Covidien acquired healthcare services company Aspect Medical Systems for 210M USD

Acquisition Highlights
  • This is Covidien’s 1st transaction in the Healthcare Services sector.
  • This is Covidien’s 10th largest (disclosed) transaction.
  • This is Covidien’s 5th transaction in the United States.
  • This is Covidien’s 3rd transaction in Massachusetts.

M&A Deal Summary
Date 2009-11-06
Target Aspect Medical Systems
Sector Healthcare Services
Buyer(s) Covidien
Deal Type Add-on Acquisition
Deal Value 210M USD

Target

Aspect Medical Systems

Norwood, Massachusetts, United States
Aspect Medical Systems, Inc. a market leader in brain monitoring technology. Aspect's Bispectral Index technology directly measures the effects of anesthetics and sedatives on the brain and has been used to assess more than 7.5 million patients.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Covidien

Dublin, Ireland
Category Company
Sector Medical Products
Employees38,500
Revenue 10.2B USD (2013)
DESCRIPTION
Covidien office in Plymouth, Minnesota.
Covidien office in Plymouth, Minnesota.

Covidien plc is a global healthcare technology and medical supplies provider. Covidien was formed as a spin-off from Tyco in 2007 and is based in Dublin, Ireland.

DEAL STATS #
Overall 6 of 21
Sector (Healthcare Services) 1 of 5
Type (Add-on Acquisition) 4 of 17
State (Massachusetts) 3 of 3
Country (United States) 5 of 16
Year (2009) 2 of 2
Size (of disclosed) 10 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-05-08 VNUS Medical Technologies

San Jose, California, United States

VNUS Medical Technologies, Inc. is a provider of medical devices for the minimally invasive treatment of venous reflux.

Buy $440M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-06-01 ev3

Plymouth, Minnesota, United States

ev3 is the endovascular technology company that brings together the right people, technology, and resources to successfully identify and provide meaningful clinical solutions to underserved markets in the endovascular field. ev3 has been dedicated to developing breakthrough and clinically proven technologies for the endovascular treatment of peripheral vascular and neurovascular diseases.

Buy $2.6B
Mergr

Product

Company

Legal